The Week in Review: China Pharma -- From Local to Global
In 2011, China life science transformed itself from an industry dominated by local, inward-looking domestic companies into a sector that has global impact, a change documented in a newly available ChinaBio® White Paper; Anaphore, a San Diego biotech startup, acquired Shanghai-based RuiYi Inc., a company with expertise in GPCRs; Qiagen will open a joint translational medicine lab with Bio-X Center of Shanghai Jiao Tong University; Fosun Pharma bought $35 million of Simcere Pharma’s shares, bringing its stake to 7.5%; Lilly wants to raise its China revenues from a current 2% up to 4% of the company’s total; Sihuan Pharma’s revenues rose 116% in 2011, winning tenders “in most regions and at stable price levels”; China Shijiazhuang Pharma (CSPC) is expanding into patented, innovative drugs; and Zhejiang Hisoar Pharma  received approval to sell its API for meropenem in Japan. More details.... Stock Symbols: (NSDQ: QGEN) (SHE: 600196) (NYSE: SCR) (NYSE: LLY) (HK: 0460) (HK: 1093) (SHE: 002099)
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here